Timmerman Report

Timmerman Report is an independent biotech publication. Subscribe today!

[Timmerman Report @timmermanreport]

Small molecules to correct disease. Listen to @srikosuri on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/qwivQfIMEc

[Timmerman Report @timmermanreport]

RevMed's Moment in the Sun, In Vivo CAR-T's Shine & NewLimit's Healthspan Haul. Catch up on a busy week in Frontpoints. https://t.co/vsKt1WNl4O

[Timmerman Report @timmermanreport]

Beyond Language: Why Drug Discovery Needs a Different Kind of AI. Guest editorial by Woody Sherman of PsiThera. https://t.co/RHiMQmGzIy

[Timmerman Report @timmermanreport]

Reimagining Science for the AI Era. Listen to @beckypferdehirt CEO of Radial @AsteraInstitute discuss the $500M nonprofit seeking to create better conditions for AI in biology. Sponsors: @AlphaSenseInc Dash Bio. https://t.co/FBraq3no2Z

[Timmerman Report @timmermanreport]

Biotech in the Balance: Saving a Strategic Industry in an Age of Public Distrust. Listen to @jmaxlevin discuss his new book on The Long Run. Sponsored by: @AlphaSenseInc & Dash Bio. https://t.co/M6IT7KMW6D

[Timmerman Report @timmermanreport]

UCB Takes Over Candid, Odyssey's IPO & Makary's Rough Week.
https://t.co/8Luc66Il6n

[Timmerman Report @timmermanreport]

Orexin drugs for narcolepsy and more. Alkermes Chairman and CEO Richard Pops is the latest guest on The Long Run podcast. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/QgBtp52Fwb

[Timmerman Report @timmermanreport]

An IPO Trio, Veradermics' Hair Loss Win, & Erasca's Rough Week. The weekly Frontpoints column. https://t.co/IQBQHPgnCV

[Timmerman Report @timmermanreport]

Biotech IPO Scorecard: Avalyn Pharma joins the Class of 2026. Seaport Therapeutics and Hemab Therapeutics next in line. Read more on how the IPO Class of 2026 is doing on TR. https://t.co/fWLFMN92NS

[Timmerman Report @timmermanreport]

Lilly Buys In Vivo CAR-T, Psychedelics in the Fast Lane, & Nektar Surges on Hair Loss Drug. https://t.co/anBKqtzklo

[Timmerman Report @timmermanreport]

Small Molecule Synthesis Made Faster: Martin Burke is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/CQeYz75rSv

[Timmerman Report @timmermanreport]

Progress for Sickle Cell Disease: Novo's Oral Pill Passes Phase III. https://t.co/98cWJlv10G

[Timmerman Report @timmermanreport]

RevMed's Groundbreaking Data, Lilly Acquires CrossBridge & Kailera's $625M IPO. Frontpoints. https://t.co/8gdP1WlfIp

[Timmerman Report @timmermanreport]

PhaseV Steps Up for Young Cancer Researchers. New Major Sponsor of Timmerman Traverse for Damon Runyon Cancer Research. Next trip: Sierras, Aug. 2-5. https://t.co/Pzz68lWyEU

[Timmerman Report @timmermanreport]

Big Monday: RevMed, Spyre, Ideaya, Allogene & Telix Make News. https://t.co/7lPtqbzAcv

[Timmerman Report @timmermanreport]

Two interesting cancer drug startups profiled this week in TR. San Diego-based Sidewinder Therapeutics https://t.co/DRFKsrm4wi and Cambridge, Mass.-based Stipple Bio. https://t.co/rSPQIE0TVg

[Timmerman Report @timmermanreport]

Computation, Chemistry & Culture for Drug Discovery. Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by: @AlphaSenseInc and Dash Bio. https://t.co/dohaavq6xQ

[Timmerman Report @timmermanreport]

Stipple Bio, Discovering New Cancer Drug Targets, Secures $100M. https://t.co/cCoHLtjmgb

[Timmerman Report @timmermanreport]

Lilly Buys Centessa, Alumis & Takeda Showdown, and Blackstone's Megafund. The weekly review in Frontpoints. https://t.co/HZdr74wQlm

[Timmerman Report @timmermanreport]

Sleep Medicine Heats Up as Lilly Enters Arena with Takeda, Alkermes. https://t.co/HH7xFPxzZp